A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: Comparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyeongsoo | - |
dc.contributor.author | Kim, Tae-Hoon | - |
dc.contributor.author | Cha, Myung-Jin | - |
dc.contributor.author | Lee, Jung Myung | - |
dc.contributor.author | Park, Junbeom | - |
dc.contributor.author | Park, Jin-Kyu | - |
dc.contributor.author | Kang, Ki-Woon | - |
dc.contributor.author | Shim, Jaemin | - |
dc.contributor.author | Uhm, Jae-Sun | - |
dc.contributor.author | Kim, Jun | - |
dc.contributor.author | Park, Hyung Wook | - |
dc.contributor.author | Choi, Eue-Keun | - |
dc.contributor.author | Kim, Jin-Bae | - |
dc.contributor.author | Kim, Changsoo | - |
dc.contributor.author | Lee, Young Soo | - |
dc.contributor.author | Joung, Boyoung | - |
dc.date.accessioned | 2021-09-02T23:25:12Z | - |
dc.date.available | 2021-09-02T23:25:12Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2017-11 | - |
dc.identifier.issn | 1738-5520 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/81705 | - |
dc.description.abstract | Background and Objectives: The aging population is rapidly increasing, and atrial fibrillation (AF) is becoming a significant public health burden in Asia, including Korea. This study evaluated current treatment patterns and guideline adherence of AF treatment. Methods: In a prospective observational registry (COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF] registry), 6,275 patients with nonvalvular AF were consecutively enrolled between June 2016 and April 2017 from 10 tertiary hospitals in Korea. Results: The AF type was paroxysmal, persistent, and permanent in 65.3%, 30.0%, and 2.9% of patients, respectively. Underlying structural heart disease was present in 11.9%. Mean CHA(2)DS(2)-VASc was 2.7 +/- 1.7. Oral anticoagulation (OAC), rate control, and rhythm control were used in 70.1%, 53.9%, and 54.4% of patients, respectively. OAC was performed in 82.7% of patients with a high stroke risk. However, antithrombotic therapy was inadequately used in 53.4% of patients with a low stroke risk. For rate control in 192 patients with low ejection fraction (<40%), ss-blocker (65.6%), digoxin (5.2%), or both (19.3%) were adequately used in 90.1% of patients; however, a calcium channel blocker was inadequately used in 9.9%. A rhythm control strategy was chosen in 54.4% of patients. The prescribing rate of class Ic antiarrythmics, dronedarone, and sotalol was 16.9% of patients with low ejection fraction. Conclusion: This study shows how successfully guidelines can be applied in the real world. The nonadherence rate was 17.2%, 9.9%, and 22.4% for stroke prevention, rate control, and rhythm control, respectively. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC CARDIOLOGY | - |
dc.subject | ANTITHROMBOTIC THERAPY | - |
dc.subject | MEDICARE BENEFICIARIES | - |
dc.subject | WARFARIN | - |
dc.subject | STROKE | - |
dc.subject | ANTICOAGULATION | - |
dc.subject | RISK | - |
dc.subject | DABIGATRAN | - |
dc.subject | ABLATION | - |
dc.subject | COHORT | - |
dc.title | A Prospective Survey of Atrial Fibrillation Management for Real-world Guideline Adherence: Comparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF) Registry | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shim, Jaemin | - |
dc.identifier.doi | 10.4070/kcj.2017.0146 | - |
dc.identifier.scopusid | 2-s2.0-85039866096 | - |
dc.identifier.wosid | 000418292300010 | - |
dc.identifier.bibliographicCitation | KOREAN CIRCULATION JOURNAL, v.47, no.6, pp.877 - 887 | - |
dc.relation.isPartOf | KOREAN CIRCULATION JOURNAL | - |
dc.citation.title | KOREAN CIRCULATION JOURNAL | - |
dc.citation.volume | 47 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 877 | - |
dc.citation.endPage | 887 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002288311 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ANTITHROMBOTIC THERAPY | - |
dc.subject.keywordPlus | MEDICARE BENEFICIARIES | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | ANTICOAGULATION | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | ABLATION | - |
dc.subject.keywordPlus | COHORT | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Anticoagulant agent | - |
dc.subject.keywordAuthor | Guidelines adherence | - |
dc.subject.keywordAuthor | Registry | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.